MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

6.950 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.950
Bid (Size) 6.660 (1)
Ask (Size) 7.000 (5)
Prev. Close 6.950
Today's Range 6.950 - 6.950
52wk Range 4.810 - 8.645
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
6 Best-Performing Robinhood Stocks Of 2022
The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a brutal start to 2022, down 12.1% year-to-date. Robinhood Markets Inc (NASDAQ: HOOD) has been one of the worst performers of all so far this year,... 
Via Benzinga

Performance

YTD
+0.43%
+0.43%
1 Month
-3.47%
-3.47%
3 Month
-16.06%
-16.06%
6 Month
-3.07%
-3.07%
1 Year
+20.24%
+20.24%

More News

Read More
7 Smart Stocks to Buy Now Under $10
Via InvestorPlace
Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings
Via Benzinga
This Coal Company's 1-Year Return Handily Beats Moderna, Catalyst Pharmaceuticals, Globalstar And Dogecoin
Via Benzinga
Catalyst Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Recap: Catalyst Pharmaceuticals Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Via Benzinga
Earnings Scheduled For March 16, 2022
Via Benzinga
Earnings Preview For Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
7 of the Top-Rated Pharmaceutical Stocks for Q1
Via InvestorPlace
The Top 3 Robinhood Stocks of 2021
Via InvestorPlace
47 Biggest Movers From Yesterday
Via Benzinga
If You Invested $1,000 In Catalyst Pharmaceuticals Stock One Year Ago, Here's How Much You'd Have Now
Via Benzinga
Topics Stocks
Exposures US Equities
Catalyst Pharmaceuticals, inc (CPRX) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Via Benzinga
3 Low-Priced Stocks That Make Smart Bets
Via InvestorPlace
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Via Benzinga
Catalyst Pharmaceuticals Stock Reaches Resistance Level, Looks Ready To Break Out
Via Benzinga
Why Are Catalyst Pharma Shares Trading Higher On Thursday?
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story